AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation
Genes · 2026
DOI: 10.3390/genes17091016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, 2026. Verfasst von Takuya Tokunaga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, MicroRNAs, Pyrimidines, Acrylamides. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, KAKENHI.
Abstract (Originalsprache)
Background/Objective: An analysis of microRNA (miRNA) expression signatures in lung adenocarcinoma (LUAD) harboring EGFR mutations revealed that multiple miRNAs, including miR-126-3p, were suppressed in cancer tissues. This study focused on miR-126-3p and aimed to identify therapeutic target genes regulated by miR-126-3p in LUAD harboring EGFR mutations and evaluate their potential for combination therapy with EGFR tyrosine kinase inhibitors.
Methods
The antitumor function of miR-126-3p was analyzed by the ectopic expression of miR-126-3p into LUAD cells with EGFR mutation. The target genes of miR-126-3p were identified through an analysis of the TargetScan, Genecodis 4 and TCGA databases. The Chou–Talalay method was used to determine the potential synergistic effects of selected drug combinations.
Results
The expression of miR-126-3p attenuated the malignant transformation of LUAD cells through targeting the “EGFR tyrosine kinase inhibitor resistance pathway”. We focused on AKT2 among the genes involved in this pathway. Capivasertib was recently approved as the first inhibitor of oncogenic AKT signaling. Therefore, we investigated the effect of combination therapy comprising osimertinib and capivasertib on LUAD cell viability. Combination therapy synergistically reduced cell viability in both PC9 and H1975 cells, with combination index values of 0.61 and 0.14, respectively, at Fa = 0.5.
Conclusions
Our miRNA-based analysis is an excellent strategy for identifying therapeutic targets that enhance the effects of EGFR inhibitors on LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Thoracic Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
- Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
- Department of Breast and Thyroid Surgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima 890-8520, Japan.
- Department of Functional Genomics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
ORCID-Profile: Takuya Tokunaga, Aya Harada Takeda, Yuya Tomioka, Ayako Nagata, Mayuko Kato, Keiko Mizuno, Kazuhiro Ueda, Naohiko Seki
Förderung
- Japan Society for the Promotion of Science
- KAKENHI
Zitieren
APA
Tokunaga, T., Ishihara, Y., Takeda, A. H., Tomioka, Y., Nagata, A., Kato, M., Suetsugu, T., Mizuno, K., Ueda, K., & Seki, N. (2026). AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation. Genes. https://doi.org/10.3390/genes17091016
Vancouver
Tokunaga T, Ishihara Y, Takeda AH, Tomioka Y, Nagata A, Kato M, et al. AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation. Genes. 2026. doi:10.3390/genes17091016
BibTeX
@article{Tokunaga2026,
author = {Tokunaga, Takuya and Ishihara, Yuka and Takeda, Aya Harada and Tomioka, Yuya and Nagata, Ayako and Kato, Mayuko and Suetsugu, Takayuki and Mizuno, Keiko and Ueda, Kazuhiro and Seki, Naohiko},
title = {AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma with EGFR Mutation},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17091016}
}
EUVIMED